Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Pediatric Transplants

Twice daily i.v. bolus tacrolimus infusion for GVHD prophylaxis in children undergoing stem cell transplantation

Bone Marrow Transplantation volume 47, pages 1415–1418 (2012)Cite this article

Subjects

Abstract

Tacrolimus is routinely administered for GVHD prophylaxis as a 24-h continuous infusion that requires a dedicated i.v. line and thus becomes logistically difficult to administer, especially in young pediatric patients. We investigated the safety and efficacy of twice daily bolus infusions of i.v. tacrolimus in 33 children undergoing hematopoietic stem cell transplantation (HSCT) at our institution. Tacrolimus was started at an initial dose of 0.015 mg/kg i.v. bolus administered as a 2-h infusion and then given at every 12 h to maintain a trough drug level between 5–15 ng/mL. Patients also received short-course MTX (66%) or mycophenolate mofetil (34%) in combination with tacrolimus. No acute infusional toxicities were observed with bolus infusions of i.v. tacrolimus. Nephrotoxicity occurred in 14/33 (42%) patients and 48% developed hypertension (HT). Almost all (94%) patients required magnesium supplements to maintain magnesium (Mg) levels ⩾1.5 mg/dL. In all, 3 (9%) patients developed severe sinusoidal obstruction syndrome (SOS). One patient developed posterior reversible leuko-encephalopathy syndrome (PRES) and one additional patient had tremors. The prevelance of these side-effects was similar to those reported for continuous i.v. administration. In all, 28% of the evaluable patients developed acute GVHD⩾grade II, though the incidence of severe (grade III–IV) GVHD was only 7%. These results suggest that intermittent bolus i.v. tacrolimus administration is a safe and effective method of GVHD prophylaxis in children.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Tanaka H, Kuroda A, Marusawa H, Hashimoto M, Hatanaka H, Kino T et al. Physicochemical properties of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant Proc 1987; 19(5 Suppl 6): 11–16.

    CAS  PubMed  Google Scholar 

  2. Bierer BE, Hollander G, Fruman D, Burakoff SJ . Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology. Curr Opin Immunol 1993; 5: 763–773.

    Article  CAS  PubMed  Google Scholar 

  3. Jacobson P, Uberti J, Davis W, Ratanatharathorn V . Tacrolimus: a new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation. Bone Marrow Transplant 1998; 22: 217–225.

    Article  CAS  PubMed  Google Scholar 

  4. Hiraoka A, Ohashi Y, Okamoto S, Moriyama Y, Nagao T, Kodera Y et al. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. Bone Marrow Transplant 2001; 28: 181–185.

    Article  CAS  PubMed  Google Scholar 

  5. Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062–2068.

    CAS  PubMed  Google Scholar 

  6. Boswell GW, Bekersky I, Fay J, Wingard J, Antin J, Weisdorf D et al. Tacrolimus pharmacokinetics in BMT patients. Bone Marrow Transplant 1998; 21: 23–28.

    Article  CAS  PubMed  Google Scholar 

  7. Yanik G, Levine JE, Ratanatharathorn V, Dunn R, Ferrara J, Hutchinson RJ . Tacrolimus (FK506) and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogeneic stem cell transplantation. Bone Marrow Transplant 2000; 26: 161–167.

    Article  CAS  PubMed  Google Scholar 

  8. Yanagisawa R, Katsuyama Y, Shigemura T, Saito S, Tanaka M, Nakazawa Y et al. Engraftment syndrome, but not acute GVHD, younger age, CYP3A5 or MDR1 polymorphisms, increases tacrolimus clearance in pediatric hematopoietic SCT. Bone Marrow Transplant 2011; 46: 90–97.

    Article  CAS  PubMed  Google Scholar 

  9. Wingard JR, Nash RA, Przepiorka D, Klein JL, Weisdorf DJ, Fay JW et al. Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation. Biol Blood Marrow Transplant 1998; 4: 157–163.

    Article  CAS  PubMed  Google Scholar 

  10. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.

    CAS  PubMed  Google Scholar 

  11. Wong R, Beguelin GZ, de Lima M, Giralt SA, Hosing C, Ippoliti C et al. Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2003; 122: 128–134.

    Article  CAS  PubMed  Google Scholar 

  12. Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M et al. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 571–575.

    Article  PubMed  Google Scholar 

  13. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255–267.

    Article  CAS  PubMed  Google Scholar 

  14. Fay JW, Wingard JR, Antin JH, Collins RH, Pineiro LA, Blazar BR et al. FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogenic bone marrow transplantation. Blood 1996; 87: 3514–3519.

    CAS  PubMed  Google Scholar 

  15. Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92: 2303–2314.

    CAS  PubMed  Google Scholar 

  16. Navaneethan SD, Sankarasubbaiyan S, Gross MD, Jeevanantham V, Monk RD . Tacrolimus-associated hypomagnesemia in renal transplant recipients. Transplant Proc 2006; 38: 1320–1322.

    Article  CAS  PubMed  Google Scholar 

  17. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS . A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63: 977–983.

    Article  CAS  PubMed  Google Scholar 

  18. Mayer AD, Dmitrewski J, Squifflet JP, Besse T, Grabensee B, Klein B et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64: 436–443.

    Article  CAS  PubMed  Google Scholar 

  19. Mueller AR, Platz KP, Christe W, Bechstein WO, Blumhardt G, Neuhaus P . Severe neurotoxicity after liver transplantation: association between FK 506 therapy and hepatitis C virus disease. Transplant Proc 1994; 26: 3131–3132.

    CAS  PubMed  Google Scholar 

  20. Wijdicks EF, Wiesner RH, Dahlke LJ, Krom RA . FK506-induced neurotoxicity in liver transplantation. Ann Neurol 1994; 35: 498–501.

    Article  CAS  PubMed  Google Scholar 

  21. Osunkwo I, Bessmertny O, Harrison L, Cheung YK, Van de Ven C, del Toro G et al. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients. Biol Blood Marrow Transplant 2004; 10: 246–258.

    Article  CAS  PubMed  Google Scholar 

  22. Shaw PJ, Kan F, Woo Ahn K, Spellman SR, Aljurf M, Ayas M et al. Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors. Blood 2010; 116: 4007–4015.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Weisdorf D, Hakke R, Blazar B, Miller W, McGlave P, Ramsay N et al. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation 1991; 51: 1197–1203.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pediatric Hematology/Oncology/BMT and Pharmacy, Nationwide Children’s Hospital, The Ohio State University, Columbus, OH, USA

    M Skeens, V Pai, A Garee, A M Termuhlen, R P S Bajwa, T G Gross & S Soni

Authors
  1. M Skeens
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V Pai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Garee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A M Termuhlen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R P S Bajwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T G Gross
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Soni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Skeens.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Skeens, M., Pai, V., Garee, A. et al. Twice daily i.v. bolus tacrolimus infusion for GVHD prophylaxis in children undergoing stem cell transplantation. Bone Marrow Transplant 47, 1415–1418 (2012). https://doi.org/10.1038/bmt.2012.59

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2012.59

Keywords

Search

Advanced search

Quick links